Sanofi signs a deal with Ablynx that could earn the Belgian biotech firm as much as 2.4 billion euros

News Hour:

French drugmaker Sanofi boosted its early-stage pipeline in immunology on Thursday by signing a deal with Ablynx that could earn the Belgian biotech firm as much as 2.4 billion euros ($2.8 billion).

Initial payments are a lot less, with Ablynx receiving an upfront payment of 23 million euros and 8 million in research funding, but big milestones will kick in if any of the experimental projects achieve commercial success, reports Reuters.

The deal gives Sanofi access to a total of eight of Ablynx’s so-called nanobody medicines, which are derived from camel and llama antibodies. The focus is on developing products to treat immune-mediated inflammatory diseases, the companies said. Shares in Ablynx rose more than 6 percent in early trading on news of the tie-up.

For Sanofi, the deal expands the company’s drug discovery efforts in immunology at a time when it is launching a promising new treatment for severe eczema.


This article has been posted by a News Hour Correspondent. For queries, please contact through [email protected]
No Comments

Translate this News

Join the Facebook Group

Click here to join the Facebook group of News Hour

Popular Posts

Sacred Games exposes Rajshri Deshpande nude [video]
Paperfly launches delivery services covering 64 districts in Bangladesh
The miracle of Hyperbaric Oxygen Therapy (HBOT) and its potential in Bangladesh
Shaon is not the only heir to Humayun Ahmed’s intellectual property: Nuhash Humayun
Eiza Gonzalez accidentally show Josh Duhamel Naked video on Instagram
Workshop to formulate nutrition action plan held in Nilphamari


News of the Month

Scroll Up
%d bloggers like this: